← Back to headlines
Jim Cramer Advises Caution on ImmunityBio
Jim Cramer recommended waiting for more clarity regarding ImmunityBio before investors consider a serious evaluation of the company's stock.
21 Apr, 17:19 — 21 Apr, 17:19
Sources
Showing 1 of 1 sources
Related Stories
Cornerstone Funds Declare Monthly Dividends and Announce 2026/2027 Distributions
3h ago
The OLB Group Reports Q2 Financials; FinVolution Group to Announce Results
5h ago
Mark Cuban and Tech Founders Oppose California Wealth Tax Proposal
7h ago
Greece to Save €2 Billion by Early Debt Repayment in 2026
8h ago